Bill Boyle

Bill Boyle is a senior executive with extensive experience in the pharmaceutical and biotechnology industries, currently serving as a Senior Research Fellow at BioAtla, Inc., a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment.12

Professional Experience

Dr. Boyle has over 28 years of experience in the pharmaceutical and biotechnology sectors.2 His career at BioAtla includes:

• Senior Research Fellow (Current position)
• Advisor (August 2021 - Present)
• Chief Science Officer and VP Translational Medicine (May 2013 - September 2020)

Other Notable Positions

• Owner of Peninsula BioPharma (January 2010 - Present)
• Associate Professor of Medicine/Pulmonary at UCLA David Geffen School of Medicine (March 2014 - January 2022)
• Founder, President, and CSO of AnaptysBio (November 2005 - January 2010)
• VP Research at Protein Pathways (October 2001 - January 2003)
• Director of Research at Amgen (April 1990 - October 2001)

Expertise and Contributions

Dr. Boyle specializes in the discovery and development of biologics, including therapeutic antibodies and recombinant proteins.2 His work at BioAtla focuses on developing novel monoclonal antibody and cell-based therapeutics using proprietary technologies such as Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).3

Recent Work

Dr. Boyle is currently involved in presenting research on BioAtla's novel therapies. He is scheduled to give an oral presentation at the Society for Melanoma Research 21st International Congress in October 2024, discussing evalstotug (BA3071), a conditionally active biologic anti-CTLA-4 antibody designed for improved efficacy and reduced toxicity in cancer treatment.1

Bill Boyle's extensive experience and leadership roles in both startup and multinational pharmaceutical companies have positioned him as a key figure in the development of innovative cancer therapies and biologics.4